19Th Meeting of the Irish Society of Human Genetics, Friday 9Th September 2016

Total Page:16

File Type:pdf, Size:1020Kb

19Th Meeting of the Irish Society of Human Genetics, Friday 9Th September 2016 Ulster Med J 2017;86(1):55-68 Abstracts 19th Meeting of the Irish Society of Human Genetics, Friday 9th September 2016. Belfast City Hospital SPOKEN PAPERS: DM Lambert1, SA Lynch1, R Marron1, D Gray2, EP Treacy1. S01. Deep phenotyping and genomic analysis for Behcet’s 1National Rare Disease Office, Mater Misericordiae Hospital, disease Dublin 7, 2National Clinical Programme for Rare Diseases, RCPI. A Coleman1, F McKinley2, A Gough2, N Wheatley2, H Xu3, AJ The National Rare Disease Office (NRDO), initiated in June 2015, McKnight1. collates and disseminates Irish rare disease (RD) information. The prevalent nature of RD (1 in 16 of the population, approximately 1 2 Centre for Public Health, Queen’s University of Belfast, Behcets 80% of which has a genetic basis) and the burden to the health care 3 UK, Centre for Experimental Medicine, Queen’s University of system is under-recognised and a neglected public health issue. Belfast. Awareness of rare diseases is a challenge, especially for GPs who each care for > 90 RD patients. Behcet’s disease (BD) is a complex, multifactorial rare disease, which is poorly understood. Genetic and environmental factors The NRDO has made 58 presentations, lectures and publications contribute to BD, but the process of diagnosis is challenging with and received numerous enquiries (58% of contacts from patients/ inconsistent clinical manifestations. A recent survey of individuals families, 25% from health care professionals and 4% researchers). living with rare disease(s) in Northern Ireland revealed ~50% of Mapping Irish RD clinical and research expertise is developing 1 individuals receive ≥1 misdiagnosis with /20 seeing >10 doctors. through Orphanet Ireland. Enrolment of clinical expert centres has increased by 50%,but only <10% of the most prevalent RDs Individuals with BD report a range of symptoms, which are are represented. This reflects well-developed services for some variable in onset, severity, and frequency for this systemic conditions, (e.g. vasculitis and ALS), but more disparate services vasculitis. Patients describe prolonged journeys to diagnosis with for others (intellectual disability and multisystemic RD). A lack of multiple healthcare professionals and medical specialties; there is coding and/or registries makes it difficult to identify rare patients no BD specialist in Northern Ireland. Using invitations via social within hospital systems. Numerous cross-border initiatives seek to media, voluntary groups, and direct contact we are using surveys maximize clinical and research outcomes through collaboration. incorporating micro-narratives, one-to-one semi-structured However, < 1% of Irish RD research and <30% of RD clinical interviews, and focus groups to collect detailed family histories trials are registered on Orphanet. For European recognition and and stressor information to help characterise recurrent features in participation, Ireland must make its RD research visible, and ‘count’ patients living with BD and their relatives in Northern Ireland. RD patients and activity. Irish patients will be disadvantaged unless BD is most often reported in populations along the Silk Road. we develop systems to prepare for entry to European Reference The highest prevalence is reported in Turkey at 20-420/100,000, Networks and become “trial ready”. While progress is slow, these compared 1.5/100,000 individuals in the UK. Mapping through are early days and we are optimistic about future developments. general practitioners revealed a much higher than expected S03. PTEN Hamartoma Tumour Syndrome Screening Audit – prevalence of 12.6/100,000 in the Northern Ireland population. Northern Ireland 2016 Clusters were observed in Co. Down and Co. Antrim and plotted with social-demographic information. This high ‘UK’ prevalence RS Moore1, V McConnell1. and the identification of several families with multiple members diagnosed makes NI ideal to explore genetic and epigenetic risk 1Clinical Genetics Department, Belfast City Hospital, 51 Lisburn factors for BD. Road, Belfast BT9 7AB. This project involves deep phenotyping and strategies to improve Aims: To assess the tumour surveillance advice given to patients recognition of Behcet’s disease, build collaborative partnerships, in Northern Ireland with confirmed PTEN hamartoma tumour improve data collection, enhance training, and information sharing. syndrome (HTS). S02. Capturing Irish Rare Disease activity, a must for improved Methods: We used the surveillance advice laid out by the Pan cross border care and research Thames Cancer Genetics Group in 2014 to benchmark our UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk). The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited and the new creation is licensed under identical terms. 56 The Ulster Medical Journal patients against. A coding search was carried out on our regional previously reported in literature to be associated aggressive MTC information management system to identify all patients with a presentation, yet remains untested for in the routine diagnosis confirmed diagnosis. The written/ electronic notes of these patients of MTC. Supported by findings from shallow whole genome were reviewed. We adhered to the National PTEN audit inclusion sequencing, we report for the first time in thyroid cancer, the criteria of including patients older than16 years, those with a occurrence of a catastrophic “chromothripsis-like pattern” (CTLP) pathogenic/likely pathogenic PTEN mutation or at 50% risk and event, which involved shattering of chromosome 4 leading to those who had received advice between 01/08/10 - 01/08/2015. complete abrogation of normal chromosomal function, in addition to dramatic wide-spread copy number aberrations (CNA), across Results: 21 patients were identified. All patients had a pathogenic both primary tumour and bone marrow samples. We further PTEN mutation. 6 children were excluded. 1 adult was excluded describe the presence of loss-of-heterozygosity (LOH) in key genes due to lack of documented advice. 6 patients had a cancer diagnosis. involved in DNA repair mechanism pathways such as ATM, which 9 patients had a positive family history of cancer. Annual breast possibly facilitated the CTLP event, in addition to LOH in other screening was recommended for 67% of patients which involved disease-associated genes such as ALK and NOTCH1 as key drivers mammography in 83% and MRI in 17%. Annual thyroid USS and of the aggressive and rapidly fatal clinical course in this patient and TFTs were recommended for 54% and 31% of patients respectively. unresponsiveness to the standard-of-care targeted agent chosen. 16% of female patients had gynaecology referrals completed. Given a possible rapid generation of tumor neo-antigens as a result An annual dermatological review was recommended for 23% of of the CTLP event, immunotherapy may have been more suitable patients. Widely variable colonoscopy and renal USS screening as a treatment option. Moreover, the presence of disease-associated was recommended for 77% and 65% of patients respectively. No SNP’s within the RET proto-oncogene, support their inclusion as cases of Lhermitte-Duclos disease were identified vs 12% in the part of routine RET genetic testing for aggressive MTC cases. national UK audit. These results provide a rationale for application of comprehensive genomic analysis of cancers presenting with unusually aggressive Conclusions: There is a need for regional PTEN tumour behavior to facilitate more appropriate therapeutic options and surveillance guidelines to be produced and implemented through a diagnoses. regional PTEN specialist clinic. S05. Target 5000: Genetic characterisation of a cohort of S04. Post-mortem examination of an aggressive case of inherited retinal degeneration (IRD) patients medullary thyroid carcinoma characterized by catastrophic genomic abnormalities A Dockery1, M Carrigan1, C Malone2, D Keegan3, K Stevenson3, J Silvestri4, A Green5, J McCourt6, P Humphries1, PF Kenna1,2, GJ D Kelly1,2*, S Das3,4*, B Moran3,4*, K Han2,5, N Mulligan2,5, C Farrar1. Barrett2,5, PG Buckley6, P Mc Mahon1,2, J McCaffrey1,2, HF Van 7 3,4 7 8 3 Essen , K Connor , B Ylstra , D Lambrechts , WM Gallagher , 1The School of Genetics & Microbiology, Trinity College Dublin, 3,4§ 1,2§ DP O’Connor , CM Kelly *Equal Contribution, § Senior co- Dublin 2, Ireland, 2Royal Victoria Eye and Ear Hospital, Dublin authors. 2, Ireland, 3The Mater Misericordiae Hospital, Dublin 7, Ireland, 4The Royal Victoria Hospital, Belfast, Northern Ireland, 5Our 1Department of Medical Oncology, Mater Misericordiae Lady’s Children’s Hospital, Crumlin, Dublin, Ireland, 6RCSI University Hospital, Eccles St. Dublin 7. 2Conway Institute, Clinical Research Centre, Smurfit Building, Beaumont Hospital, University Hospital Dublin, Belfield, Dublin 4, Ireland. 3Cancer Beaumont Road, Dublin 9, Ireland. Biology and Therapeutics lab, Conway Institute, University 4 College Dublin, Belfield, Dublin 4, Ireland. Department of The Target 5000 research project aims to provide genetic testing Molecular and Cellular Therapeutics, Royal College of Surgeons for the estimated 5,000 people in Ireland who have an inherited 5 in Ireland, 123 St. Stephens Green, Dublin 2, Ireland. Department retinal condition. Many clinical trials are available for patients of cellular pathology,
Recommended publications
  • The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc Oncogenesis
    The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc oncogenesis By Yuting Sun This thesis is submitted in fulfilment of the requirements for the degree of Doctor of Philosophy at the University of New South Wales Children’s Cancer Institute Australia for Medical Research School of Women’s and Children’s Health, Faculty of Medicine University of New South Wales Australia August 2014 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Sun First name: Yuting Other name/s: Abbreviation for degree as given in the University calendar: PhD School : School of·Women's and Children's Health Faculty: Faculty of Medicine Title: The Roles of Histone Deacetylase 5 and the Histone Methyltransferase Adaptor WDR5 in Myc oncogenesis. Abstract 350 words maximum: (PLEASE TYPE) N-Myc Induces neuroblastoma by regulating the expression of target genes and proteins, and N-Myc protein is degraded by Fbxw7 and NEDD4 and stabilized by Aurora A. The class lla histone deacetylase HDAC5 suppresses gene transcription, and blocks myoblast and leukaemia cell differentiation. While histone H3 lysine 4 (H3K4) trimethylation at target gene promoters is a pre-requisite for Myc· induced transcriptional activation, WDRS, as a histone H3K4 methyltransferase presenter, is required for H3K4 methylation and transcriptional activation mediated by a histone H3K4 methyltransferase complex. Here, I investigated the roles of HDAC5 and WDR5 in N-Myc overexpressing neuroblastoma. I have found that N-Myc upregulates HDAC5 protein expression, and that HDAC5 represses NEDD4 gene expression, increases Aurora A gene expression and consequently upregulates N-Myc protein expression in neuroblastoma cells.
    [Show full text]
  • RNA Epigenetics: Fine-Tuning Chromatin Plasticity and Transcriptional Regulation, and the Implications in Human Diseases
    G C A T T A C G G C A T genes Review RNA Epigenetics: Fine-Tuning Chromatin Plasticity and Transcriptional Regulation, and the Implications in Human Diseases Amber Willbanks, Shaun Wood and Jason X. Cheng * Department of Pathology, Hematopathology Section, University of Chicago, Chicago, IL 60637, USA; [email protected] (A.W.); [email protected] (S.W.) * Correspondence: [email protected] Abstract: Chromatin structure plays an essential role in eukaryotic gene expression and cell identity. Traditionally, DNA and histone modifications have been the focus of chromatin regulation; however, recent molecular and imaging studies have revealed an intimate connection between RNA epigenetics and chromatin structure. Accumulating evidence suggests that RNA serves as the interplay between chromatin and the transcription and splicing machineries within the cell. Additionally, epigenetic modifications of nascent RNAs fine-tune these interactions to regulate gene expression at the co- and post-transcriptional levels in normal cell development and human diseases. This review will provide an overview of recent advances in the emerging field of RNA epigenetics, specifically the role of RNA modifications and RNA modifying proteins in chromatin remodeling, transcription activation and RNA processing, as well as translational implications in human diseases. Keywords: 5’ cap (5’ cap); 7-methylguanosine (m7G); R-loops; N6-methyladenosine (m6A); RNA editing; A-to-I; C-to-U; 2’-O-methylation (Nm); 5-methylcytosine (m5C); NOL1/NOP2/sun domain Citation: Willbanks, A.; Wood, S.; (NSUN); MYC Cheng, J.X. RNA Epigenetics: Fine-Tuning Chromatin Plasticity and Transcriptional Regulation, and the Implications in Human Diseases. Genes 2021, 12, 627.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Enzyme DHRS7
    Toward the identification of a function of the “orphan” enzyme DHRS7 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Selene Araya, aus Lugano, Tessin Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt (Fakultätsverantwortlicher) und Prof. Dr. Michael Arand (Korreferent) Basel, den 26.6.2018 ________________________ Dekan Prof. Dr. Martin Spiess I. List of Abbreviations 3α/βAdiol 3α/β-Androstanediol (5α-Androstane-3α/β,17β-diol) 3α/βHSD 3α/β-hydroxysteroid dehydrogenase 17β-HSD 17β-Hydroxysteroid Dehydrogenase 17αOHProg 17α-Hydroxyprogesterone 20α/βOHProg 20α/β-Hydroxyprogesterone 17α,20α/βdiOHProg 20α/βdihydroxyprogesterone ADT Androgen deprivation therapy ANOVA Analysis of variance AR Androgen Receptor AKR Aldo-Keto Reductase ATCC American Type Culture Collection CAM Cell Adhesion Molecule CYP Cytochrome P450 CBR1 Carbonyl reductase 1 CRPC Castration resistant prostate cancer Ct-value Cycle threshold-value DHRS7 (B/C) Dehydrogenase/Reductase Short Chain Dehydrogenase Family Member 7 (B/C) DHEA Dehydroepiandrosterone DHP Dehydroprogesterone DHT 5α-Dihydrotestosterone DMEM Dulbecco's Modified Eagle's Medium DMSO Dimethyl Sulfoxide DTT Dithiothreitol E1 Estrone E2 Estradiol ECM Extracellular Membrane EDTA Ethylenediaminetetraacetic acid EMT Epithelial-mesenchymal transition ER Endoplasmic Reticulum ERα/β Estrogen Receptor α/β FBS Fetal Bovine Serum 3 FDR False discovery rate FGF Fibroblast growth factor HEPES 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid HMDB Human Metabolome Database HPLC High Performance Liquid Chromatography HSD Hydroxysteroid Dehydrogenase IC50 Half-Maximal Inhibitory Concentration LNCaP Lymph node carcinoma of the prostate mRNA Messenger Ribonucleic Acid n.d.
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Systematic Knockdown of Epigenetic Enzymes Identifies a Novel Histone Demethylase PHF8 Overexpressed in Prostate Cancer with An
    Oncogene (2012) 31, 3444–3456 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion M Bjo¨rkman1,PO¨stling1,2,VHa¨rma¨1, J Virtanen1, J-P Mpindi1,2, J Rantala1,4, T Mirtti2, T Vesterinen2, M Lundin2, A Sankila2, A Rannikko3, E Kaivanto1, P Kohonen1, O Kallioniemi1,2,5 and M Nees1,5 1Medical Biotechnology, VTT Technical Research Centre of Finland, and Center for Biotechnology, University of Turku and A˚bo Akademi University, Turku, Finland; 2Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland and 3HUSLAB, Department of Urology, University of Helsinki, Helsinki, Finland Our understanding of key epigenetic regulators involved in finger proteins like PHF8, are activated in subsets of specific biological processes and cancers is still incom- PrCa’s and promote cancer relevant phenotypes. plete, despite great progress in genome-wide studies of the Oncogene (2012) 31, 3444–3456; doi:10.1038/onc.2011.512; epigenome. Here, we carried out a systematic, genome- published online 28 November 2011 wide analysis of the functional significance of 615 epigenetic proteins in prostate cancer (PrCa) cells. We Keywords: prostate cancer; epigenetics; histone used the high-content cell-spot microarray technology and demethylase; migration; invasion; PHF8 siRNA silencing of PrCa cell lines for functional screening of cell proliferation, survival, androgen receptor (AR) expression, histone methylation and acetylation. Our study highlights subsets of epigenetic enzymes influencing different cancer cell phenotypes.
    [Show full text]
  • Pflugers Final
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Serveur académique lausannois A comprehensive analysis of gene expression profiles in distal parts of the mouse renal tubule. Sylvain Pradervand2, Annie Mercier Zuber1, Gabriel Centeno1, Olivier Bonny1,3,4 and Dmitri Firsov1,4 1 - Department of Pharmacology and Toxicology, University of Lausanne, 1005 Lausanne, Switzerland 2 - DNA Array Facility, University of Lausanne, 1015 Lausanne, Switzerland 3 - Service of Nephrology, Lausanne University Hospital, 1005 Lausanne, Switzerland 4 – these two authors have equally contributed to the study to whom correspondence should be addressed: Dmitri FIRSOV Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925406 Fax: ++ 41-216925355 e-mail: [email protected] and Olivier BONNY Department of Pharmacology and Toxicology, University of Lausanne, 27 rue du Bugnon, 1005 Lausanne, Switzerland Phone: ++ 41-216925417 Fax: ++ 41-216925355 e-mail: [email protected] 1 Abstract The distal parts of the renal tubule play a critical role in maintaining homeostasis of extracellular fluids. In this review, we present an in-depth analysis of microarray-based gene expression profiles available for microdissected mouse distal nephron segments, i.e., the distal convoluted tubule (DCT) and the connecting tubule (CNT), and for the cortical portion of the collecting duct (CCD) (Zuber et al., 2009). Classification of expressed transcripts in 14 major functional gene categories demonstrated that all principal proteins involved in maintaining of salt and water balance are represented by highly abundant transcripts. However, a significant number of transcripts belonging, for instance, to categories of G protein-coupled receptors (GPCR) or serine-threonine kinases exhibit high expression levels but remain unassigned to a specific renal function.
    [Show full text]
  • Kdm3b Haploinsufficiency Impairs the Consolidation of Cerebellum
    Kim et al. Mol Brain (2021) 14:106 https://doi.org/10.1186/s13041-021-00815-5 RESEARCH Open Access Kdm3b haploinsufciency impairs the consolidation of cerebellum-dependent motor memory in mice Yong Gyu Kim1,2†, Myeong Seong Bak1,2†, Ahbin Kim1,2†, Yujin Kim3,4, Yun‑Cheol Chae5, Ye Lee Kim2,6, Yang‑Sook Chun1,2,6, Joon‑Yong An3,4, Sang‑Beom Seo5, Sang Jeong Kim1,2,7* and Yong‑Seok Lee1,2,7* Abstract Histone modifcations are a key mechanism underlying the epigenetic regulation of gene expression, which is critically involved in the consolidation of multiple forms of memory. However, the roles of histone modifcations in cerebellum‑dependent motor learning and memory are not well understood. To test whether changes in histone / methylation are involved in cerebellar learning, we used heterozygous Kdm3b knockout (Kdm3b+ −) mice, which show reduced lysine 9 on histone 3 (H3K9) demethylase activity. H3K9 di‑methylation is signifcantly increased / selectively in the granule cell layer of the cerebellum of Kdm3b+ − mice. In the cerebellum‑dependent optokinetic / response (OKR) learning, Kdm3b+ − mice show defcits in memory consolidation, whereas they are normal in basal oculomotor performance and OKR acquisition. In addition, RNA‑seq analyses revealed that the expression levels of several plasticity‑related genes were altered in the mutant cerebellum. Our study suggests that active regulation of histone methylation is critical for the consolidation of cerebellar motor memory. Keywords: Kdm3b, Optokinetic response (OKR), Histone modifcation, Cerebellum Introduction Post-translational modifcations of histone pro- One of the hallmarks of memory consolidation is that it teins, such as acetylation and methylation, determine requires changes in gene expression [1, 2].
    [Show full text]
  • Vitamin D and the Epigenome
    REVIEW ARTICLE published: 29 April 2014 doi: 10.3389/fphys.2014.00164 Vitamin D and the epigenome Irfete S. Fetahu , Julia Höbaus and Eniko˝ Kállay* Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Edited by: Epigenetic mechanisms play a crucial role in regulating gene expression. The main Carsten Carlberg, University of mechanisms involve methylation of DNA and covalent modifications of histones by Eastern Finland, Finland methylation, acetylation, phosphorylation, or ubiquitination. The complex interplay of Reviewed by: different epigenetic mechanisms is mediated by enzymes acting in the nucleus. Patsie Polly, The University of New South Wales, Australia Modifications in DNA methylation are performed mainly by DNA methyltransferases Moray J. Campbell, Roswell Park (DNMTs) and ten-eleven translocation (TET) proteins, while a plethora of enzymes, Cancer Institute, USA such as histone acetyltransferases (HATs), histone deacetylases (HDACs), histone *Correspondence: methyltransferases (HMTs), and histone demethylases (HDMs) regulate covalent histone Eniko˝ Kállay, Department of modifications. In many diseases, such as cancer, the epigenetic regulatory system is often Pathophysiology and Allergy Research, Medical University of disturbed. Vitamin D interacts with the epigenome on multiple levels. Firstly, critical genes Vienna, Währinger Gürtel 18-20, in the vitamin D signaling system, such as those coding for vitamin D receptor (VDR)and A-1090 Vienna, Austria the enzymes 25-hydroxylase (CYP2R1), 1α-hydroxylase (CYP27B1), and 24-hydroxylase e-mail: enikoe.kallay@ (CYP24A1) have large CpG islands in their promoter regions and therefore can be silenced meduniwien.ac.at by DNA methylation. Secondly, VDR protein physically interacts with coactivator and corepressor proteins, which in turn are in contact with chromatin modifiers, such as HATs, HDACs, HMTs, and with chromatin remodelers.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • The Emerging Role of Histone Lysine Demethylases in Prostate Cancer
    Crea et al. Molecular Cancer 2012, 11:52 http://www.molecular-cancer.com/content/11/1/52 REVIEW Open Access The emerging role of histone lysine demethylases in prostate cancer Francesco Crea1*, Lei Sun3, Antonello Mai4, Yan Ting Chiang1, William L Farrar3, Romano Danesi2 and Cheryl D Helgason1,5* Abstract Early prostate cancer (PCa) is generally treatable and associated with good prognosis. After a variable time, PCa evolves into a highly metastatic and treatment-refractory disease: castration-resistant PCa (CRPC). Currently, few prognostic factors are available to predict the emergence of CRPC, and no curative option is available. Epigenetic gene regulation has been shown to trigger PCa metastasis and androgen-independence. Most epigenetic studies have focused on DNA and histone methyltransferases. While DNA methylation leads to gene silencing, histone methylation can trigger gene activation or inactivation, depending on the target amino acid residues and the extent of methylation (me1, me2, or me3). Interestingly, some histone modifiers are essential for PCa tumor- initiating cell (TIC) self-renewal. TICs are considered the seeds responsible for metastatic spreading and androgen- independence. Histone Lysine Demethylases (KDMs) are a novel class of epigenetic enzymes which can remove both repressive and activating histone marks. KDMs are currently grouped into 7 major classes, each one targeting a specific methylation site. Since their discovery, KDM expression has been found to be deregulated in several neoplasms. In PCa, KDMs may act as either tumor suppressors or oncogenes, depending on their gene regulatory function. For example, KDM1A and KDM4C are essential for PCa androgen-dependent proliferation, while PHF8 is involved in PCa migration and invasion.
    [Show full text]